BioMarin Pharmaceuticals Inc (BMRN)
BioMarin Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare genetic diseases. Founded in 1997, it specializes in treatments for conditions such as enzyme deficiencies, genetic disorders, and other underserved medical needs, offering its products primarily in the areas of neurology, inherited metabolic disorders, and hematology.
Company News
The Motley Fool podcast discusses potential acquisition targets, Tesla's decision to abandon its Dojo supercomputer project, and explores possible buyout candidates in various sectors including tech, pharmaceuticals, and apparel.
BioMarin reported strong Q2 earnings, beating estimates with $1.44 per share and $825.41 million in sales. The company discontinued its preclinical drug candidate BMN 390 but advanced BMN 333 with promising Phase 1 study results, targeting a potential 2030 launch.
Inozyme Pharma announced the postponement of its 2025 Annual Meeting of Stockholders due to the previously announced acquisition by BioMarin Pharmaceutical Inc. The company is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics targeting the PPi-Adenosine Pathway.
The article identifies three stocks - Humana, Elevance Health, and BioMarin - that are currently oversold based on their Relative Strength Index (RSI) readings, suggesting potential for a rebound.
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.